Richard Wolf Product Re-Launch Plan (Myanmar â Phase 2)
Hereâs a complete Business Development (BD) Plan for the Re-Launch of Richard Wolf (RW) Products in Myanmar, structured to address supplier concerns, internal training, product re-registration, and focused marketing in Urology and Laparoscopy.
đ Richard Wolf Product Re-Launch Plan (Myanmar â Phase 2)
đŻ Goal:
Re-establish Richard Wolf in the Myanmar medical device market with focus on Urology & Laparoscopy, improve distributor credibility, and build long-term trust with supplier through structured execution and market feedback.
đ 1. Internal Staff Training
Objective:
Ensure that the sales, clinical, service, and back-office teams have updated, product-specific knowledge to professionally represent Richard Wolf.
Actions:
Conduct 3-day hybrid training:
Day 1: Product Knowledge (Urology, Laparoscopy, ENT â overview)
Day 2: Application Demonstration, Handling, and Scope Anatomy
Day 3: Objection Handling, Competitor Comparison, and Sales Pitching
Trainers:
RW Regional Trainer (virtual or in-person)
Clinical Champion from our distributor team
Deliverables:
Training certificate for each attendee
Role-specific Quick Reference Guides
Internal FAQ and Pricing Sheet
đŚ 2. Product Re-Registration with Myanmar FDA
Objective:
Ensure regulatory compliance and uninterrupted legal distribution under local entity.
Actions:
Confirm latest Richard Wolf Dossiers (IFU, ISO, CE/FDA certs, specs, video link)
Translate updated labels & IFU into Myanmar language
Appoint Regulatory Agent and submit within Month 1â2
Target Completion:
â FDA Submission â Month 1
â FDA Approval â Month 3 (expected)
đ 3. Focus Areas: Urology & Laparoscopy
đ§Ş Urology Focus:
Flagship Product: TUR Resectoscope Set (monopolar & bipolar)
Target Users: MOHS, Private Hospitals, Urologists in Yangon, Mandalay, Naypyitaw
KOL Engagement: Invite top 3 urologists for feedback trial
Value Prop: German-made, durable, and compatible with major energy platforms
đĽ Laparoscopy Focus:
Flagship Product: 10mm 30° Laparoscope + ENDOCAM Logic HD
Target Users: General surgeons, GYN in private hospitals
Application: Cholecystectomy, appendectomy, oncology
Value Prop: Long scope life, HD integration, competitive cost vs Karl Storz/Medtronic
đ§° 4. Procurement of Demo Set
Required Demo Items:
1x TUR Set (Sheath, Working Element, Bridge, Loop)
1x Laparoscope Set (10mm 30°, Light Cable, Camera Head)
1x ENDOCAM Logic Camera Unit (HD or 4K)
1x Spine System (optional if KOL interest arises)
Budget & Justification:
Demo set is essential for:
Product training
KOL trials
CME events
Early adoption campaigns
Action:
Submit formal PO request to supplier with commitment plan.
đ 5. Timeline & Milestones
| Phase | Activities | Timeline |
|---|---|---|
| Month 1 | Staff training, demo request, FDA prep | Jan 2025 |
| Month 2 | FDA submission, demo arrival, KOL engagement | Feb 2025 |
| Month 3 | FDA approval, soft re-introduction to users | Mar 2025 |
| Month 4 | CME event + relaunch campaign | Apr 2025 |
| Month 5â6 | Hospital trials, feedback loop, sales ramp-up | MayâJun 2025 |
đŁ 6. Product Re-Launch Strategy (Myanmar)
Re-Launch Theme:
âPrecision Reimagined â Trusted German Endoscopy Returnsâ
Key Actions:
CME Launch Event:
Invite 20â30 surgeons
Hands-on demo stations
KOL testimonial video
Marketing Collateral:
Brochures in English & Myanmar
Scope comparison charts (RW vs Karl Storz)
Demo Videos & QR code access
Sales Campaigns:
âTry & Buyâ for TUR sets
Bundle pricing for Laparoscopy kits
Distributor sales targets with quarterly review
Supplier Reassurance:
Submit re-launch timeline & training photos
Share early market feedback from KOLs
Quarterly sales reports with lead feedback
Offer co-branding opportunity at CME
â Summary: Key Commitments to Supplier
| Concern | Our Response |
|---|---|
| Previous slow traction | New focused relaunch with KOL trial + marketing plan |
| Low visibility | Dedicated demo units + CME events planned |
| Weak sales staff | Full product training and internal certification |
| Unregistered products | Fast-tracked re-registration process initiated |
| Lack of commitment | Monthly reporting + dedicated product champion assigned |
Would you like this turned into:
đ PDF Re-Launch Plan for sharing with Richard Wolf HQ?
đď¸ PowerPoint Launch Presentation for internal stakeholders?
đď¸ Email draft to supplier summarizing this plan?
Let me know how youâd like to move forward.
đ FAQs Ă 5 â Dual Language (1 Sentence Format)
Q1: Why is staff retraining essential before re-launching RW products?
(áááááááŻáˇ Richard Wolf ááŻááşááŻááşááťáŹá¸ááᯠááźááşáááşááááşáááşáááşáᎠáááşáááşá¸ááťáŹá¸ááᯠááźááşááąáˇááťááˇáşáááźááşá¸ áĄááąá¸ááźáŽá¸áááŹá¸?)
A1: Because proper knowledge builds surgeon confidence and avoids past performance gaps.
(ááąáŹááşá¸áá˝ááşááąáŹáĄáááááŹáážáááźááşá¸áááş áááŹáááşááťáŹá¸á ááŻáśááźááşáážáŻááᯠáááşááąáŹááşááąá¸ááźáŽá¸ ááááşáĄáážáŹá¸ááťáŹá¸ááᯠáááźá áşáĄáąáŹááşááŹáá˝ááşáááŻááşáááşá)
Q2: What are the two focus areas for this re-launch?
(ě´ë˛ ááááşáááşáážáŻáá˝ááş áĄááááĄáŹááŻáśá ááŻááşáážáŻ ááąá áážá áşááŻá ááŹáá˛?)
A2: Urology and Laparoscopy are the key focus specialties.
(Urology áážááˇáş Laparoscopy áááş áĄááááĄáŹááŻáśá ááŻááşáááˇáş áĄáá°á¸ááŻááŹáááťáŹá¸ ááźá áşáááşá)
Q3: Why is demo equipment purchase important?
(Demo áĄááąáŹááşá¸ááźááá ášá ááşá¸ áááşáá°ááźááşá¸áĄááąá¸ááźáŽá¸áááˇáşáĄááźáąáŹááşá¸áááşá¸áááŹáá˛?)
A3: It allows KOL trials, hands-on training, and builds trust with new users.
(áĄááááááŹáááşááťáŹá¸ááž á ááşá¸áááşáĄááŻáśá¸ááźáŻáááŻááşááźáŽá¸ áááşáá˝áąáˇááąáˇááťááˇáşáážáŻááťáŹá¸ááᯠááźáŻááŻááşáááŻááşáááşá)
Q4: What must be done before legally selling the product in Myanmar?
(ááźááşááŹáááŻááşááśáá˝ááş áááŹá¸áááşááąáŹááşá¸ááťáááş áááááááŻáˇááŹááŻááşááááşáááşá¸?)
A4: The product must be re-registered with Myanmar FDA.
(ááźááşáᏠFDA áá˝ááş ááŻááşááŻááşáĄáŹá¸ ááźááşáááşáážááşááŻáśáááşááááşá)
Q5: How can we rebuild supplier confidence after a weak first launch?
(ááááĄááźáááşááááşáááşáážáŻ ááĄáąáŹááşááźááşáááˇáşáĄá፠áá°áááŻááşááŻááşáá°á ááŻáśááźááşáážáŻááᯠáááşáááŻáˇááźááşáááşáááşááąáŹááşáááŻááşááá˛?)
A5: By showing structured plans, KOL engagement, and quarterly performance reporting.
(áĄá áŽáĄá ááşááźááˇáşá áŻáśááźááşá¸á áááŹáááşáááşá¸áááŻá¸ááźááˇáşááťáŹá¸ááźááˇáş áááşáá˝á˛ááźááşá¸áážááˇáş ááŻáśá¸ááá áşááźáááş á áŽááśááááşá¸áĄáąáŹááşááźááşáážáŻ ááźááşáááşáááşááźááźááşá¸ááźááˇáş ááźááşáááşáááşááąáŹááşáááŻááşáááşá)
There are no comments for now.